Clifton Park, NY, United States of America

Helene Decornez

This inventor holds 6 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Oncotherapy Science, Incorporated, Affinium Pharmaceuticals, Inc.. Active years: 2010-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Helene Decornez. Retrieved from https://idiyas.com/inventor/helene-decornez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 9.8

ph-index = 3

Forward Citations = 31(Granted Patents)

Company Filing History:

4 out of 150

Oncotherapy Science, Incorporated

patents

2 out of 33

Affinium Pharmaceuticals, Inc.

patents

Years Active: 2010-2019

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10508109 - Bicyclic compound and use thereof for inhibiting SUV39H2 (2019-12-17),

2. 9453025 - Tricyclic compounds and PBK inhibitors containing the same (2016-09-27),

3. 9120749 - Quinoline derivatives and MELK inhibitors containing the same (2015-09-01),

4. 8962648 - Tricyclic compounds and PBK inhibitors containing the same (2015-02-24),

5. 8450307 - Therapeutic agents, and methods of making and using the same (2013-05-28),

6. 7790709 - Heterocyclic compounds, methods of making them and their use in therapy (2010-09-07),

Title: The Innovative Journey of Helene Decornez

Introduction

Helene Decornez is a notable inventor based in Clifton Park, NY, with a remarkable portfolio that includes six patents. Her work focuses primarily on the development of innovative compounds that show promise in treating various diseases, particularly cancer.

Latest Patents

Among Helene's latest patents is a groundbreaking product involving a bicyclic compound aimed at inhibiting SUV39H2. This invention represents a significant advancement in the quest for effective treatments. Additionally, she has developed tricyclic compounds that act as PBK inhibitors, which are vital for addressing PBK-related diseases, including cancer.

Career Highlights

Throughout her career, Helene has worked with reputable organizations such as Oncotherapy Science, Inc. and Affinium Pharmaceuticals, Inc. Her contributions in these companies have played a crucial role in the advancement of pharmaceutical research and development.

Collaborations

Helene has collaborated with prominent figures in her field, including Yo Matsuo and Shoji Hisada. These partnerships have further enriched her work and helped in pushing the boundaries of innovation in the development of therapeutic compounds.

Conclusion

Helene Decornez exemplifies the spirit of innovation in the field of pharmaceuticals. Her dedication to research and development has resulted in patents that not only enhance scientific knowledge but also offer hope for treating complex diseases. Her journey serves as an inspiration to aspiring inventors around the world.

Profile summary based on public USPTO records.